SOX plus sintilimab vs P-SOX vs SOX as neoadjuvant therapy in advanced gastric cancer: Efficacy and safety

Table 3 Single-factor Cox regression analysis

Variable	Z	HR (95%CI)	P value
Age
≤ 60		Reference
> 60	1.059	1.189 (0.863, 1.638)	0.290
Gender
Male		Reference
Female	1.286	1.285 (0.877, 1.883)	0.198
ASA
1 + 2		Reference
3	1.184	1.292 (0.846, 1.973)	0.236
Differentiation
Well		Reference
Moderate	1.511	1.469 (0.892, 2.420)	0.131
Poorly	4.465	2.614 (1.714, 3.986)	< 0.001
cT stage
2		Reference
3	-0.739	0.853 (0.561, 1.299)	0.460
4	3.075	2.049 (1.297, 3.237)	0.002
cN stage
Negative		Reference
Positive	4.551	2.417 (1.653, 3.535)	< 0.001
cTNM
II		Reference
IIIA	1.560	1.750 (0.866, 3.533)	0.119
IIIB	5.165	2.915 (1.942, 4.374)	< 0.001
IIIC	7.878	5.049 (3.375, 7.554)	< 0.001
RECIST 1.1
Ineffective		Reference
Effective	-3.636	0.550 (0.398, 0.759)	< 0.001
Lauren
Diffuse		Reference
Mixed	-1.152	0.811 (0.569, 1.158)	0.249
Intestinal	-0.203	0.953 (0.600, 1.514)	0.839
Tumor location
Upper		Reference
Middle	0.741	1.163 (0.780, 1.736)	0.459
Lower	-0.093	0.981 (0.654, 1.471)	0.926
TRG
Ineffective		Reference
Effective	3.110	2.084 (1.312, 3.310)	0.002
Tumor diameter
≤ 2		Reference
2-5	3.658	2.026 (1.388, 2.958)	< 0.001
≥ 5	5.225	2.922 (1.954, 4.368)	< 0.001

ASA: American Society of Anesthesiologists Score; RECIST: Response Evaluation Criteria in Solid Tumors; TRG: Tumor regression grade.